FDA approves Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome – Arrowhead
Arrowhead Pharmaceuticals, Inc. announced that the FDA has approved Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with… read more.

